Danaher set to buy purification consumables firm Phenomenex

By Dan Stanton contact

- Last updated on GMT

Image: iStock/sumos
Image: iStock/sumos

Related tags: High performance liquid chromatography

Danaher Corporation will further extend its presence in the life sciences space through the acquisition of separations and purification firm Phenomenex.

Phenomenex, based in Torrence, California, offers separations and purification consumables for liquid and gas chromatography applications and is set to become a standalone company within Danaher, the firms announced today.

“We are thrilled to have Phenomenex join Danaher’s life sciences portfolio of businesses, which include SCIEX, Beckman Coulter Life Sciences, Pall, Leica Microsystems and Molecular Devices,” ​Danaher’s EVP Dan Daniel said.

Financial details were not revealed, but Phenomenex’ portfolio of 7,000 products and its 700 staff are expected to move over to Danaher by the end of the year.

However, Evercore ISI analyst Ross Muken said in a note the firm may have paid upwards of $700m for Phenomenex, and its foray into “a high growth life science consumable business”​ came as no surprise.

“This was certainly a deal chosen on culture/fit and not just price paid as multiples are well below what an asset like this would fetch in a full blown auction,”​ he noted, adding the acquisition is this is “one of the great consumable assets that remained in Life Sci Tools.”

With Phenomenex’s product lines including Kinetix, Aeris, and Gemini HPLC/UHPLC (High Performance Liquid Chromatography/Ultra Performance Liquid Chromatography), Muken added Danaher would now be competing directly against Agilent and Waters in the small molecule chromatography space.

Danaher already has an established presence in the bioprocessing downstream space, through the $14bn acquisition of filtration, separation and purification firm Pall Corporation completed in September 2015​.

Terrell Mathews, a Phenomenex spokesperson, confirmed it will be a standalone company within Danaher’s Lifesciences portfolio and added there will be no cross duplication of key technologies between Phenomenex and Pall.

However we were told that "in the future, Phenomenex may be able to be a sales channel for Pall consumable items."

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us


View more